Human Leukocyte Antigen HLA Testing

Human Leukocyte Antigen HLA Testing Market Outlook

The global Human Leukocyte Antigen (HLA) Testing market is projected to reach approximately USD 2.7 billion by 2035, growing at a compound annual growth rate (CAGR) of around 10.6% during the forecast period from 2025 to 2035. This robust growth can be attributed to several key factors, including the rising incidence of autoimmune diseases and an increasing number of organ transplants, which are critically dependent on HLA matching for transplant success. Additionally, advances in molecular biology techniques and the growing demand for personalized medicine are also contributing to the market's expansion. The increasing prevalence of chronic diseases has led to heightened awareness regarding HLA typing, thereby boosting market demand. Furthermore, the ongoing research and development activities in the field of immunology are expected to enhance the capabilities of HLA testing methods, spurring further market growth.

Growth Factor of the Market

The growth of the HLA testing market is significantly driven by the increasing number of organ transplantation procedures performed globally. As organ transplant rates rise, the demand for precise HLA typing becomes paramount to ensure donor-recipient compatibility, reducing the risk of transplant rejection. Furthermore, the surge in personalized medicine and targeted therapies has emphasized the need for accurate HLA testing, as these treatments often depend on an individual's genetic makeup. The market is also supported by advancements in technology, such as Next-Generation Sequencing (NGS), which provides more accurate and comprehensive HLA typing results. Additionally, the growing awareness among healthcare professionals regarding the importance of HLA testing in disease prevention and treatment is further propelling the market forward. The presence of robust research funding and initiatives aimed at improving transplantation outcomes is also expected to provide a significant boost to the HLA testing market.

Key Highlights of the Market

• Increased demand for HLA testing due to the rising number of organ transplantation surgeries.
• Technological advancements, including Next-Generation Sequencing, enhancing the accuracy and efficiency of HLA typing.
• Growing prevalence of autoimmune diseases necessitating accurate HLA typing for diagnosis and treatment.
• Expanding applications of HLA testing in pharmacogenomics and disease association studies.
• Continuous research and development efforts leading to innovative HLA testing methodologies.

By Product Type

Polymerase Chain Reaction (PCR)-Based HLA Typing

PCR-based HLA typing is a widely used method in the HLA testing market due to its speed and efficiency. This technique amplifies specific DNA segments, allowing for the rapid identification of HLA genes. PCR-based methods provide high sensitivity and specificity, making them suitable for various applications, including organ transplantation and disease association studies. The simplicity of the process and the relatively low cost compared to other molecular techniques contribute to the popularity of PCR-based HLA typing. Furthermore, as the demand for HLA testing grows, laboratories are increasingly incorporating PCR-based methods to meet clinical needs, thereby driving market growth in this segment.

Sequencing-Based HLA Typing

Sequencing-based HLA typing employs traditional Sanger sequencing or next-generation sequencing methodologies to provide a comprehensive analysis of HLA genes. This method is particularly advantageous for its ability to identify polymorphisms in HLA genes, which are crucial for accurate typing. The sequencing approach is essential for complex cases, such as those involving multi-allelic and high-resolution typing, which are increasingly relevant in the context of organ transplantation. The increasing adoption of sequencing technologies in clinical laboratories is expected to bolster this market segment, as healthcare providers seek more detailed genetic information for better patient outcomes.

Serology-Based HLA Typing

Serology-based HLA typing involves testing serum samples to identify HLA antibodies. This method, while traditional, plays a significant role in pre-transplant testing to assess potential sensitization of recipients. The serological approach is beneficial in determining the presence of anti-HLA antibodies, which can significantly affect transplant success. Despite the rise of molecular techniques, serology remains relevant, particularly in specific clinical contexts, thus ensuring its continued presence in the HLA testing market. The integration of serological methods with molecular techniques is also enhancing the overall efficiency of HLA compatibility assessments.

Next-Generation Sequencing (NGS)-Based HLA Typing

Next-Generation Sequencing (NGS)-based HLA typing represents a paradigm shift in HLA testing, offering unprecedented accuracy and high-throughput capabilities. NGS allows for the simultaneous sequencing of multiple HLA loci, which is critical for comprehensive typing in complex cases such as multi-organ transplants. The technology's capability to resolve high-resolution alleles significantly reduces the risk of transplant rejection and improves matching outcomes. The decreasing costs of NGS platforms and increasing availability of sequencing services are key drivers of this market segment, attracting more laboratories to adopt NGS for routine HLA testing.

Microarray-Based HLA Typing

Microarray-based HLA typing is an emerging technology that uses DNA microarrays to analyze multiple HLA loci simultaneously. This high-throughput technology allows for the rapid processing of a large number of samples, making it an attractive option for laboratories handling extensive testing. The efficiency and speed of microarray-based assays, combined with their ability to provide detailed information regarding HLA alleles, position them as a valuable tool in clinical and research settings. As laboratories seek to improve their throughput and reduce turnaround times, the adoption of microarray-based HLA typing is anticipated to grow, further contributing to the overall expansion of the market.

By Polymerase Chain Reaction

Real-Time PCR

Real-Time PCR is a significant advancement in polymerase chain reaction technology that allows for the quantitative detection of DNA in real-time during the amplification process. This method is particularly beneficial for HLA typing, as it provides rapid results and allows for the monitoring of the amplification process. The ability to quantify the amount of target DNA helps in minimizing errors associated with conventional PCR, thus enhancing the accuracy of HLA typings. With the growing demand for timely results in transplantation settings, Real-Time PCR is increasingly adopted in clinical laboratories, contributing to its growth in the HLA testing market.

High-Resolution PCR

High-Resolution PCR is a specialized technique that enables the amplification of HLA genes with a focus on resolving closely related alleles. This method is crucial for applications requiring high specificity, such as in cases of ambiguous HLA typing results from standard PCR methods. High-Resolution PCR enhances the reliability of HLA typing by providing clearer differentiation among similar alleles, which is essential for successful transplantation outcomes. As the need for high-accuracy typing increases in clinical settings, the demand for High-Resolution PCR is expected to rise correspondingly within the HLA testing market.

By Generation Sequencing

Sanger Sequencing

Sanger sequencing has been the gold standard in DNA sequencing for over three decades, and it continues to play a vital role in HLA typing. This method is particularly effective for resolving complex HLA genotypes due to its high accuracy and reliability. In transplantation settings, Sanger sequencing is often used for confirmatory typing when other methods yield inconclusive results. The robustness of Sanger sequencing in providing detailed information about HLA alleles ensures its relevance in the market, especially for high-resolution typing needs in clinical applications.

Next-Generation Sequencing (NGS)

As previously discussed, Next-Generation Sequencing (NGS) is revolutionizing HLA typing with its high-throughput capabilities and accuracy. NGS allows for the simultaneous analysis of multiple alleles across various HLA loci, making it an ideal choice for complex cases. The increasing adoption of NGS in clinical laboratories is driven by its ability to provide comprehensive data that assists in donor-recipient matching and improves patient outcomes. Additionally, NGS continues to evolve, with advancements in bioinformatics tools that facilitate data interpretation, thus expanding its application in the HLA testing market.

By Application

Transplantation

The transplantation sector is one of the primary applications driving the demand for HLA testing. Accurate HLA typing is crucial in organ transplantation to ensure compatibility between donors and recipients, thereby minimizing the risk of graft rejection and enhancing transplant success rates. As the number of organ transplant procedures increases globally, the need for reliable HLA testing methods is becoming increasingly important. Moreover, advancements in HLA typing technologies that provide higher resolution and faster results are further contributing to the growth of this segment, as transplant clinics strive to improve patient care.

Disease Association Studies

Disease association studies utilize HLA testing to investigate the relationship between specific HLA alleles and various diseases, particularly autoimmune disorders. The identification of HLA associations can provide valuable insights into disease predisposition and progression, thereby aiding in the development of targeted therapies. As research into the genetic basis of diseases continues to advance, the demand for HLA testing in this application is expected to grow. Researchers are increasingly incorporating HLA typing into their studies, emphasizing the relevance of genetic factors in understanding complex diseases and personalizing treatment strategies.

Pharmacogenomics

Pharmacogenomics is an emerging field that examines how an individual's genetic makeup influences their response to drugs, and HLA testing plays a critical role in this area. Certain HLA alleles are associated with adverse drug reactions, making HLA typing essential for optimizing drug therapy and minimizing risks. As the pharmaceutical industry increasingly recognizes the importance of personalized medicine, the demand for HLA testing in pharmacogenomics is anticipated to rise. This application supports the trend towards individualized treatment plans, ensuring that patients receive medications tailored to their genetic profiles.

HLA-HIV Associations

HLA typing is also essential in studying the associations between HLA alleles and HIV infection. Research has shown that specific HLA alleles can influence an individual's susceptibility to HIV and their response to antiretroviral treatment. Understanding these associations can lead to better strategies for managing HIV and improving patient outcomes. As the global burden of HIV continues, the integration of HLA testing in HIV research is expected to grow, further driving the demand for HLA testing in this application.

Other Applications

Other applications of HLA testing include research in areas such as oncology, infectious diseases, and vaccine development. HLA typing is increasingly being utilized to understand the immune response to various cancers and infectious agents, aiding in the identification of potential therapeutic targets. Additionally, HLA testing is becoming integral in vaccine research to assess vaccine efficacy and design personalized vaccination strategies based on individual HLA profiles. As the scope of HLA testing expands across diverse fields, this segment of the market is poised for substantial growth, reflecting the versatility of HLA applications in modern medicine.

By Distribution Channel

Hospitals

Hospitals serve as a primary distribution channel for HLA testing, providing essential services for patient care, particularly in transplant units. With the increasing number of organ transplantations, hospitals are investing in advanced HLA typing technologies to ensure accurate compatibility testing. The presence of specialized laboratories within hospitals allows for quicker turnaround times, enabling timely decision-making in critical situations. Furthermore, hospitals are likely to adopt a combination of molecular and serological techniques to cater to varying clinical requirements, thereby driving the growth of this segment in the HLA testing market.

Diagnostic Laboratories

Diagnostic laboratories play a pivotal role in the HLA testing market by providing specialized testing services for healthcare providers. These laboratories are equipped with state-of-the-art technologies that facilitate a wide range of HLA typing methods, including PCR, sequencing, and serology. The demand for HLA testing in diagnostic labs is bolstered by their ability to offer high-throughput services and the expertise of specialized personnel in interpreting complex genetic data. As healthcare systems increasingly rely on third-party diagnostic labs for accurate HLA typing, this distribution channel is expected to experience significant growth.

Research Institutes

Research institutes are vital contributors to the HLA testing market, as they often conduct studies related to immunology, genetics, and disease associations. These institutes utilize HLA testing to explore the genetic factors that influence disease susceptibility and treatment responses. The increasing focus on translational research, aimed at bridging the gap between laboratory findings and clinical applications, is driving the demand for HLA testing in research settings. As funding for biomedical research continues to grow, the involvement of research institutes in HLA testing is anticipated to expand, stimulating further market growth.

Blood Banks

Blood banks are increasingly incorporating HLA typing into their processes to enhance the safety and efficacy of blood transfusions. HLA matching is critical in identifying compatible donors for patients at risk of transfusion-related immune reactions. By implementing HLA testing procedures, blood banks can ensure more accurate matching of donated blood to recipients, significantly improving patient outcomes. The rising awareness of the importance of HLA typing in transfusion medicine is expected to drive the growth of this segment within the HLA testing market, as blood banks strive to optimize their services.

Others

Other distribution channels for HLA testing include academic institutions, research organizations, and private clinics. These entities often conduct specialized testing for specific research purposes or offer personalized services to patients. The growth of personalized medicine and increased investment in genetic research are driving demand for HLA testing across these diverse channels. As the landscape of healthcare continues to evolve, the role of various distribution channels in facilitating access to HLA testing is becoming increasingly critical, contributing to the overall growth of the market.

By Region

The North American region dominates the global HLA testing market, driven by advanced healthcare infrastructure, high adoption rates of innovative technologies, and a robust organ transplantation program. The region's market is expected to grow at a CAGR of approximately 12.3% over the forecast period, fueled by increasing awareness of the importance of HLA testing among healthcare professionals and patients. The United States, in particular, is a major contributor to this growth, with a significant number of organ transplantations carried out annually and a wide range of HLA testing services provided by hospitals and diagnostic laboratories.

Europe is another critical region for the HLA testing market, characterized by a strong emphasis on research and development initiatives in genomics and immunology. The European market is anticipated to expand steadily, supported by increasing government funding for transplantation programs and research projects focusing on HLA typing. Countries like Germany and the United Kingdom are at the forefront of adopting advanced HLA typing technologies, which further enhances the region's market position. Meanwhile, the Asia Pacific region is witnessing rapid growth in HLA testing, driven by the rising prevalence of chronic diseases, increasing healthcare expenditures, and a growing number of transplant procedures, although the overall market size remains smaller than that of North America and Europe.

Opportunities

The HLA testing market presents numerous opportunities for growth driven by technological advancements and an increasing focus on personalized medicine. One of the most promising opportunities lies in the continued development of Next-Generation Sequencing (NGS) technologies, which offer enhanced accuracy and efficiency in HLA typing. As NGS becomes more accessible and cost-effective, its adoption in clinical settings is likely to expand, leading to improved patient outcomes and increased demand for comprehensive HLA testing. Additionally, the rise of personalized medicine, where treatments are tailored to the genetic profiles of patients, is creating a significant opportunity for HLA testing. As healthcare providers increasingly incorporate HLA testing into their treatment protocols, the market is expected to benefit greatly from this trend.

Furthermore, the growing awareness of the importance of HLA testing in disease prevention and management presents an additional avenue for market growth. As more healthcare professionals and patients recognize the critical role of HLA typing in organ transplantation, autoimmune disease diagnosis, and pharmacogenomics, the demand for accurate and timely HLA testing services will continue to rise. Additionally, the increasing collaboration between research institutions and clinical laboratories to advance HLA testing methodologies is likely to foster innovation and drive the market forward. The expansion of HLA testing into emerging markets also holds potential, as rising healthcare investments and technological advancements will facilitate the integration of HLA testing in these regions.

Threats

Despite the significant growth potential of the HLA testing market, several threats could hinder its progress. One of the primary concerns is the high costs associated with advanced HLA testing technologies, particularly Next-Generation Sequencing. While these technologies offer improved accuracy and efficiency, their initial investment and operational costs can be prohibitive for many laboratories, especially in emerging markets. Additionally, the complexity of HLA typings, which require specialized training and expertise, may pose challenges in standardizing testing practices across different laboratories. The reliance on highly skilled professionals to interpret HLA typing results could also create bottlenecks in testing capacities, potentially leading to delays in patient care.

Moreover, regulatory challenges and stringent guidelines governing HLA testing may act as a barrier to market entry for new players and the introduction of innovative technologies. As the field of genomics continues to evolve, regulatory bodies must keep pace with advancements to ensure patient safety and the reliability of testing methods. Furthermore, the global landscape of healthcare is subject to fluctuations due to economic and political factors, which could impact funding for research and development initiatives in HLA testing. As such, manufacturers and service providers must navigate these challenges carefully to maintain their competitive edge and capitalize on market opportunities.

Competitor Outlook

• Thermo Fisher Scientific
• Illumina Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• GenDx
• Merck KGaA
• Abbott Laboratories
• Eurofins Scientific
• Qiagen N.V.
• Transplant Genomics, Inc.
• HLA Lab
• Invitae Corporation
• Roche Diagnostics
• Luminex Corporation
• Fujirebio Diagnostics, Inc.

The competitive landscape of the HLA testing market is characterized by a mix of established players, emerging companies, and ongoing technological innovations. Major companies such as Thermo Fisher Scientific and Illumina Inc. are at the forefront of developing advanced HLA typing solutions, leveraging their expertise in molecular biology and genomics to enhance testing accuracy and efficiency. These companies continue to invest heavily in research and development to stay ahead of the competition and expand their product offerings. Furthermore, strategic partnerships and collaborations among key players are becoming increasingly common, as companies seek to leverage each other's strengths and resources to enhance their market presence.

In addition to established players, several emerging companies are entering the HLA testing market, offering innovative solutions and services. Companies like GenDx and Transplant Genomics, Inc. focus on niche applications within the HLA testing domain, providing specialized products that cater to specific user needs. These newcomers are often agile and responsive to market demands, allowing them to capture market share by offering unique value propositions, such as enhanced accuracy or reduced turnaround times. As the market continues to evolve, it is likely that further consolidation will occur, with larger companies acquiring smaller firms to broaden their technological capabilities and market reach.

The ongoing advancements in technology, particularly in areas such as Next-Generation Sequencing and bioinformatics, are reshaping the competitive landscape of the HLA testing market. Companies that can effectively integrate these technologies into their offerings are well-positioned to gain a competitive edge. For instance, Illumina's focus on developing NGS-based solutions for HLA typing demonstrates the potential for growth in this segment. Additionally, companies that prioritize customer-centric approaches and provide exceptional support services are likely to enhance customer loyalty and retention, further solidifying their position in the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GenDx
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HLA Lab
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Qiagen N.V.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Illumina Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Eurofins Scientific
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Invitae Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Luminex Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Beckman Coulter, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Transplant Genomics, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bio-Rad Laboratories, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Fujirebio Diagnostics, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Human Leukocyte Antigen HLA Testing Market, By Application
    • 6.1.1 Transplantation
    • 6.1.2 Disease Association Studies
    • 6.1.3 Pharmacogenomics
    • 6.1.4 HLA-HIV Associations
    • 6.1.5 Other Applications
  • 6.2 Human Leukocyte Antigen HLA Testing Market, By Product Type
    • 6.2.1 Polymerase Chain Reaction (PCR)-Based HLA Typing
    • 6.2.2 Sequencing-Based HLA Typing
    • 6.2.3 Serology-Based HLA Typing
    • 6.2.4 Next-Generation Sequencing (NGS)-Based HLA Typing
    • 6.2.5 Microarray-Based HLA Typing
  • 6.3 Human Leukocyte Antigen HLA Testing Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Diagnostic Laboratories
    • 6.3.3 Research Institutes
    • 6.3.4 Blood Banks
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Human Leukocyte Antigen HLA Testing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Human Leukocyte Antigen HLA Testing market is categorized based on

By Product Type

• Polymerase Chain Reaction (PCR)-Based HLA Typing
• Sequencing-Based HLA Typing
• Serology-Based HLA Typing
• Next-Generation Sequencing (NGS)-Based HLA Typing
• Microarray-Based HLA Typing

By Application

• Transplantation
• Disease Association Studies
• Pharmacogenomics
• HLA-HIV Associations
• Other Applications

By Distribution Channel

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Blood Banks
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Illumina Inc.
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• GenDx
• Merck KGaA
• Abbott Laboratories
• Eurofins Scientific
• Qiagen N.V.
• Transplant Genomics, Inc.
• HLA Lab
• Invitae Corporation
• Roche Diagnostics
• Luminex Corporation
• Fujirebio Diagnostics, Inc.